MedTrace Logo

Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation

NCT02584738 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2015-12-02

No results posted yet for this study

Summary

The purpose of this study is to investigate the effectiveness of nebulized magnesium sulfate in patient with moderate to severe asthma exacerbation in pediatric emergency

Conditions

Interventions

DRUG

Nebulized Magnesium Sulfate

Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4 (150 mg) per dose every 20 minutes during the first hour. will be continued with nebulized standard treatment every hour for 4 hours.

DRUG

Nebulized isotonic saline

Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic saline per dose every 20 minutes during the first hour. will be continued with nebulized standard treatment every hour for 4 hours.

DRUG

Nebulized Salbutamol

Nebulized salbutamol 2.5mg (2-5 years) or 5 mg (≥6 years)

DRUG

Ipratropium bromide

Nebulized ipratropium bromide 250 mcg

DRUG

Methylprednisolone or Prednisolone

Begin with intravenous methylprednisolone or oral prednisolone 2 mg/kg/day for each treatment

Sponsors & Collaborators

  • Hospital General Naval de Alta Especialidad - Escuela Medico Naval

    lead OTHER_GOV

Principal Investigators

  • Jesús Abisai Uicab Saucedo, Pediatrician · Secretaria de Marina

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-01-31
Completion
2018-01-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02584738 on ClinicalTrials.gov